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Abstract
Objective:  To  apply,  in  Brazil,  the  T-cell  receptor  excision  circles  (TRECs)  quantiﬁcation  tech-
nique using  real-time  polymerase  chain  reaction  in  newborn  screening  for  severe  combined
immunodeﬁciency  and  assess  the  feasibility  of  implementing  it  on  a  large  scale  in  Brazil.
Methods:  8715  newborn  blood  samples  were  collected  on  ﬁlter  paper  and,  after  DNA  elution,
TRECs were  quantiﬁed  by  real-time  polymerase  chain  reaction.  The  cutoff  value  to  determine
whether  a  sample  was  abnormal  was  determined  by  ROC  curve  analysis,  using  SSPS.
Results: The  concentration  of  TRECs  in  8,682  samples  ranged  from  2  to  2,181  TRECs/L  ofPrimary
immunodeﬁciency blood, with  mean  and  median  of  324  and  259  TRECs/L,  respectively.  Forty-nine  (0.56%)  samples
were below  the  cutoff  (30  TRECs/L)  and  were  reanalyzed.  Four  (0.05%)  samples  had  abnormal
results (between  16  and  29  TRECs/L).  Samples  from  patients  previously  identiﬁed  as  having
severe combined  immunodeﬁciency  or  DiGeorge  syndrome  were  used  to  validate  the  assay  and
 Please cite this article as: Kanegae MP, Barreiros LA, Mazzucchelli JT, Hadachi SM, Guilhoto LM, Acquesta AL, et al. Neonatal screening
or severe combined immunodeﬁciency in Brazil. J Pediatr (Rio J). 2016;92:374--80.
 This study was carried out at the Department of Immunology, Instituto de Ciências Biomédicas, Universidade de São Paulo (USP), São
aulo, SP, Brazil.
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all  of  them  showed  TRECs  below  the  cutoff.  Preterm  infants  had  lower  levels  of  TRECs  than
full-term  neonates.  The  ROC  curve  showed  a  cutoff  of  26  TRECs/L,  with  100%  sensitivity  for
detecting severe  combined  immunodeﬁciency.  Using  this  value,  retest  and  referral  rates  were
0.43% (37  samples)  and  0.03%  (3  samples),  respectively.
Conclusion:  The  technique  is  reliable  and  can  be  applied  on  a  large  scale  after  the  training  of
technical teams  throughout  Brazil.
© 2016  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Sociedade  Brasileira  de  Pediatria.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Triagem  neonatal  para  imunodeﬁciência  combinada  grave  no  Brasil
Resumo
Objetivo:  aplicar  no  Brasil  a  técnica  de  quantiﬁcac¸ão  de  T-cell  Receptor  Excision  Circles  (TRECs)
por polymerase  chain  reaction  em  tempo  real  para  triagem  neonatal  de  imunodeﬁciência  com-
binada grave  (SCID)  e  avaliar  se  é  possível  realizá-la  em  larga  escala  em  nosso  país.
Métodos:  foram  coletadas  8.715  amostras  de  sangue  de  recém-nascidos  em  papel  ﬁltro  e,  após
eluic¸ão do  DNA,  os  TRECs  foram  quantiﬁcados  por  polymerase  chain  reaction  em  tempo  real.
O valor  de  corte  para  determinar  se  uma  amostra  é  anormal  foi  determinado  pela  análise  de
curva ROC  utilizando-se  o  programa  SSPS.
Resultados:  a  concentrac¸ão  de  TRECs  em  8.682  amostras  analisadas  variou  entre  2  e  2.181
TRECs/L de  sangue,  com  média  e  mediana  de  324  e  259  TRECs/L,  respectivamente.
49 (0,56%)  amostras  ﬁcaram  abaixo  do  valor  de  corte  (30  TRECs/L)  e  foram  requantiﬁ-
cadas. Quatro  (0,05%)  mantiveram  resultados  anormais  (entre  16  e  29  TRECs/L).  Amostras
de pacientes  com  diagnóstico  clínico  prévio  de  imunodeﬁciência  combinada  grave  e  síndrome
de DiGeorge  foram  utilizadas  para  validar  o  ensaio  e  todas  apresentaram  concentrac¸ão  de  TRECs
abaixo do  valor  de  corte.  Recém-nascidos  prematuros  apresentaram  menores  níveis  de  TRECs
comparados  aos  nascidos  a  termo.  Utilizando  a  curva  ROC  em  nossos  dados,  chegamos  ao  valor
de corte  de  26  TRECs/L,  com  sensibilidade  de  100%  para  detecc¸ão  de  imunodeﬁciência  combi-
nada grave.  Utilizando  este  valor,  as  taxas  de  repetic¸ão  e  encaminhamento,  ﬁcaram  em  0,43%
(37 amostras)  e  0,03%  (3  amostras),  respectivamente.
Conclusão:  A  técnica  é  factível  e  pode  ser  implantada  em  larga  escala,  após  treinamento
técnico das  equipes  envolvidas.
©  2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Sociedade  Brasileira  de  Pediatria.  Este
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Introduction
Severe  combined  immunodeﬁciencies  (SCID)  comprises  a
heterogeneous  group  of  diseases  characterized  by  severe
defects  in  the  development  and  function  of  T,  B,  and  NK  lym-
phocytes.  They  are  recognized  as  pediatric  emergencies,  as
they  lead  to  severe  and  recurrent  infections  and  are  fatal
in  the  ﬁrst  two  years  of  life,  if  not  diagnosed  and  treated
adequately.1,2
Due  to  the  disease  severity  and  the  urgency  in  diag-
nosis  and  treatment,  in  2005,  United  States  researchers
developed  the  newborn  screening  (NBS)  for  SCID,  which  con-
sists  of  quantifying  T-cell  receptor  excision  circles  (TRECs)
using  real-time  polymerase  chain  reaction  (PCR)  (qRT-
PCR).3,4 TRECs  are  small  circular  pieces  of  DNA  formed
during  normal  thymic  processing,  when  T-cell  receptor  gene
rearrangement  occurs.  As  they  do  not  replicate  during  cell
division,  they  work  as  markers  for  the  number  of  ‘‘naïve’’
T-cells  recently  emigrated  from  the  thymus,  and  they  are
reduced  in  all  forms  of  SCID.5
In  most  cases,  NBS  is  the  only  way  to  detect  SCID  before
infections  occur,  as  more  than  80%  of  cases  have  no  family
history  of  primary  immunodeﬁciency.6
(
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A  signiﬁcant  altered  ﬁnding  observed  after  the  devel-
pment  of  neonatal  screening  was  the  disease  incidence.
s  many  children  die  before  the  diagnosis  is  attained,
he  incidence  of  SCID  was  estimated  at  0.10/10,000;  after
he  American  experience,  this  ﬁgure  is  currently  close  to
.17/10,000  (1:58,000),  or  almost  two-fold  higher.6,7
In  Brazil,  there  is  no  neonatal  screening  test  for  primary
mmunodeﬁciencies  applied  during  medical  routine  assess-
ent  and  the  diagnosis  of  these  diseases  falls  short  of  what
s  required.8--10 For  this  reason,  the  aim  of  this  study  was
o  apply  the  TRECs  quantiﬁcation  technique  by  qRT-PCR
n  the  NBS  for  severe  combined  immunodeﬁciencies  and
ssess  whether  it  is  possible  to  do  so  on  a  large  scale  in
razil.
ethods
ll  samples  were  collected  following  the  current  ethical
tandards  of  the  Research  Ethics  Committee  of  ICB-USP
Opinion  967/CEP)  and  the  parents/guardians  of  the  new-
orns  signed  the  informed  consent.  The  concentration  of
RECs  was  determined  after  blood  samples  were  collected
n  903  ﬁlter  paper  cards  through  heel  puncture,  which  is
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art  of  the  current  routine  for  newborn  screening.  Samples
rom  children  born  in  three  maternity  services  of  hospitals
nd  APAE  de  São  Paulo  (APAE-SP),  located  in  the  metropoli-
an  region  of  São  Paulo,  as  well  as  samples  collected  at
línica  de  Medicina  Preventiva  do  Pará  (CLIMEP)  were  ana-
yzed.
Disks  measuring  3.2  mm  in  diameter  were  cut  from  ﬁl-
er  paper  and  were  added  to  a  96-well  polypropylene  plate,
here  the  DNA  elution  procedure  was  carried  out,  as  pre-
iously  described.3 All  plates,  in  addition  to  the  neonates’
amples,  had  a  positive  control  (adult  blood  with  low  lev-
ls  of  TRECs),  and  a  no-target  control  (piece  of  ﬁlter  paper
ith  no  sample).  The  qRT-PCR  reaction  for  TRECs  and/or
eta-actin  was  performed  as  described.3,11 All  reagents
ere  purchased  from  Life  Technologies® (Life  Technologies,
SA).
Initially,  a  cutoff  value  of  30  TRECs/L  of  blood  was  arbi-
rarily  used  to  determine  whether  a  sample  was  normal,
ased  on  the  value  provided  by  Baker  et  al.  of  25  TRECs/L.
n  cases  where  the  result  was  below  this  value,  a  new
iece  of  the  same  sample  had  its  TRECs  analysis  repeated,
ccompanied  by  beta-actin  analysis,  as  extraction  con-
rol.  After  the  second  analysis,  the  samples  with  values
30  TRECs/L  and  beta-actin  >8000/L  were  considered
bnormal,  and  patients  were  referred  to  a  pediatric  immu-
ologist  for  consultation  and  conﬁrmatory  tests  (complete
lood  count  and  measurement  of  T,  B  lymphocytes  and  NK
ells).  Those  with  TRECs  <30/L and  beta-actin  <8000/L
ere  classiﬁed  as  inconclusive  result  and  a  new  sample  was
equested.
Data  analysis  was  carried  out  using  descriptive  statistics.
fter  applying  the  Kolmogorov--Smirnov  test,  the  data  were
ot  normally  distributed  and  were  thus  shown  as  median  and
nterquartile  values.  Comparison  of  TREC  concentrations
etween  full-term  and  preterm  newborns  was  established
sing  the  Mann--Whitney  test,  utilizing  GraphPadPrism  5.0
oftware  (GraphPadPrism,  USA).  The  cutoff  value  to  deter-
ine  whether  a  sample  was  abnormal  was  determined  byhe  ROC  curve  analysis  (area  under  the  curve)  using  SSPS
oftware  (IBM  Corp.  Released  2013,  IBM  SPSS  Statistics  for
indows,  Version  22.0,  NY,  USA).
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igure  1  Distribution  of  8682  newborns’  samples,  according  to  th
f blood.  TRECs  were  quantiﬁed  by  qRT-PCR  in  DNA  extracted  from  Kanegae  MP  et  al.
esults
amples  were  collected  from  8,715  newborns,  of  whom
,353  (38%)  were  from  CLIMEP  and  the  rest  from  hospitals
ocated  in  the  metropolitan  region  of  São  Paulo.  Of  the  total,
3  were  considered  inadequate  as  they  were  inappropri-
tely  collected.  Thus,  8,682  samples  were  analyzed  for  the
oncentration  of  TRECs,  and  the  values  in  the  ﬁrst  quan-
iﬁcation  varied  from  2  to  2,181  TRECs/L  of  blood,  with  a
ean  and  median  value  of  324  and  259  TRECs/L,  respec-
ively.  Following  the  established  protocol,  samples  below
he  cutoff  value  (30  TRECs/uL)  were  reanalyzed.  Thus,
9  (0.56%)  samples  were  requantiﬁed  and  only  four  (0.05%)
ad  abnormal  results,  with  TRECs  between  16  and  29/L.
mong  these  four  samples,  one  was  from  a  27-week  male
ewborn  (24  TRECs/L),  which  could  not  be  located  for  the
rotocol  to  be  completed.  The  three  remaining  infants  were
ssessed  and  submitted  to  the  lymphocyte  number  evalua-
ion,  whose  results  were  normal  in  all  cases.  Fig.  1  shows
he  distribution  of  samples  according  to  the  concentration
f  TRECs  obtained  at  the  ﬁrst  analysis.
To  verify  assay  efﬁcacy,  samples  from  patients  previously
iagnosed  with  SCID  (n  =  5)  and  DiGeorge  syndrome  (n  =  2)
ere  analyzed  and  used  as  controls.  All  SCID  samples  showed
RECs  values  below  3  TRECs/L,  and  the  DiGeorge  samples
howed  results  of  5  and  24  TRECs/L  (Table  1).
Part  of  the  samples  from  CLIMEP  (2,416)  contained  data
n  gestational  age:  9.9%  (239)  of  the  newborns  were  preterm
30--36  weeks  gestational  age).  That  allowed  the  compari-
on  of  the  TRECs  concentration  between  the  two  groups,
hich  allowed  the  conclusion  that  preterm  infants  have
ower  TRECs  levels  than  full-term  newborns  (Fig.  2).
Arbitrarily  using  30  TRECs/L as  the  initial  cutoff  value,
 repetition  rate  of  0.56%  was  found  (49  samples).  After
he  second  measurement,  only  4  samples  remained  with
bnormal  values,  which  resulted  in  a  referral  rate  to  a
pecialized  pediatric  service  of  0.05%.  When  analyzing  the
OC  curve  for  these  conditions  (Fig.  3),  the  cutoff  value  of
6  TRECs/L was  obtained,  with  an  area  under  the  curve
f  1.00  and  100%  sensitivity  for  detecting  SCID.  Using  this
alue,  the  retesting  and  referral  rates  were  recalculated,
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Table  1  Immunophenotyping  of  lymphocytes  in  patients  with  clinical  diagnosis  of  primary  immunodeﬁciencies  and  samples  sent  to  pediatric  immunologist  for  evaluation  after
altered neonatal  screening.
Patients  with  clinical  diagnosis  of  primary  immunodeﬁciencies Newborn  screening  samples
that  were  reanalyzed  and  sent
to  pediatric  immunologist
Patient  1 Patient  2 Patient  3 Patient  4 Patient  5 Patient  6 Patient  7 Sample  1 Sample  2
Age 2y5m  months 1y2m  months 5  months 6  months 3  months 1y11m  months 8  months 40  days 2  months  12  days
TRECs/uL  5  24  0  0  0  2  0  21  16
Diagnostic hypothesis DiGeorge  S. DiGeorge  S. SCID  SCID  SCID  (RAG1) SCID  SCID  -- --
Total lymphocytes 2614  7682b 6783  (57%) 5676  (33%) 6364  (74%) 2710a 5382  (60%) 6471
CD3 953a 3773  3615  (53.3%)  3321  (58.5%)  3451  (58.9%)  3290  (51.7%)  510  (24%)a 2852.5  (53%)  4051  (61%)
CD4 608a 954  (12%)  461.9a (6.8%)  2390  (42.1%)  342  (5.8%)a 1591  (25%)  239  (11.3%)a 1954  (36.3%)  2895  (44%)
CD4+CD45RA+CCR7+
(naïve)
2.9a (0.6%)  5.7  (0.24%)a 0.8  (0.052%)a 1260  (64.5%)
CD4+CD45RA−CCR7−
(peripheral memory)
400.5  (86.7%)b 1995  (83.5%)b 1519  (95.5%)b 216.9  (11.1%)b
CD8  289a 2675b (35%)  2815  (41.5%)b 257.7a (4.54%)  2220  (37.9%)b 1426  (22.4%)  53  (2.5%)a 710.4  (13.2%)  1019  (15%)
CD8+CD45RA+CCR7+  (naïve)  2.2  (0.08%)a 0.3  (0.13%)a 2.42  (0.17%)a 503.7  (70.9%)
CD8+CD45RA−CCR7−
(peripheral memory)
2550  (90.6%)b 165.4  (64.2%)  1176  (82.5%)b 26.8  (3.77%)
CD16+CD56+ 343  2205  (32.5%)b 1862  (32.8%)b 2354.7  (37%)b 171  (8.1%)  904.2  (16.8%)  709  (11%)
CD19 1254b 441.6  (6.5%)a 22.7  (0.4%)a 1828  (31.2%)  4.5  (0.07%)a 1294  (61%)  1130  (21%)  1092  (27%)
TRECs, T-cell receptor excision circles; DiGeorge S., DiGeorge syndrome; SCID, severe combined immunodeﬁciency; RAG1, recombination activation gene 1; CD, cluster of differentiation;
CCR7, chemokine (C-C motif) receptor 7.
a Below the 10th percentile for Brazilian children.24
b Above the 90th percentile for Brazilian children.24
378  
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Figure  2  Concentration  of  T-cell  receptor  excision  circles
(TRECs)/L for  preterm  and  full-term  infants.  TRECs  were
quantiﬁed  by  qRT-PCR  in  dried  blood  spots  of  239  preterm
(30--36 weeks)  and  2177  full-term  newborns  (37--42  weeks).
Preterm  newborns  showed  lower  TRECs  concentrations  than  the
full-term  ones  (237  TRECs/L  vs.  300  TRECs/L,  respectively;
*p <  0.05,  Mann--Whitney  test).  The  concentration  of  TRECs  is
shown in  a  boxplot  showing  median,  25th  and  75th  percentiles,
and  minimum  and  maximum  values.
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Figure  3  Receiver  operating  characteristics  (ROC)  curve  for
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6-cell receptor  excision  circles  (TRECs)  cutoff  value  of  26/L,
ith an  area  under  the  curve  of  1.00.
hich  resulted  in  0.43%  (37  samples)  and  0.03%  (3  samples),
espectively.
iscussion
CID  results  from  a  variety  of  molecular  defects,  and  the
efects  in  both  cellular  and  humoral  immunity  lead  to  sim-
lar  clinical  presentations.  In  most  cases,  symptoms  start
etween  the  second  and  third  months  of  life,  and  infec-
ious  complications  are  the  predominant  characteristic  of
a
h
tKanegae  MP  et  al.
he  disease,  with  a  preponderance  of  opportunistic  infec-
ions  (e.g., by  P.  jirovecii).  Clinical  signs  are  nonspeciﬁc
nd  include  respiratory  tract  infections,  mucocutaneous
andidiasis  resistant  to  topical  therapy,  eczematous  der-
atitis,  and  local  and  systemic  bacterial  infections  (otitis,
astoiditis,  purulent  rhinitis  and  conjunctivitis,  septic  dis-
ase,  meningitis,  arthritis,  and  local  abscesses).  Very  often,
he  ﬁrst  sign  is  a  reaction  to  the  BCG  vaccine,  which  may
resent  as  a  localized  or  disseminated  reaction.12 Severe  and
ecurrent  infections  lead  to  inadequate  growth.  Addition-
lly,  intracellular  parasites  (Listeria,  Legionella) as  well  as
iruses  (Epstein--Barr  virus  and  cytomegalovirus)  can  cause
atal  complications.13
One  multicenter  study  disclosed  the  severe  problem  of
nderdiagnosis  of  SCID  in  Brazil.  In  15  years  (1996--2010),
nly  70  cases  were  diagnosed  in  23  centers  contacted  in  the
ountry.  Considering  the  probable  incidence  of  0.17  cases
f  SCID  per  10,000  live  births  (1:58,000)  and  the  mean  of
,900,000  live  births/year  from  1996  to  2010,  750  cases  of
CID  were  expected  in  this  period.  As  only  70  were  docu-
ented,  more  than  90%  of  cases  occurred  without  adequate
iagnosis.6,10
These  numbers  clearly  show  the  difﬁculty  in  attaining
he  diagnosis  of  SCID  in  Brazil.  As  previously  mentioned,  the
igns  and  symptoms  are  nonspeciﬁc,  ranging  from  common
nfections  in  the  neonatal  stage  to  growth  difﬁculties.  Chil-
ren  born  to  families  with  previous  cases  of  SCID  can  beneﬁt
rom  the  positive  history  and  have  the  possibility  of  attaining
n  early  diagnosis.  However,  80%  of  cases  have  no  previous
istory6 and  diagnosis  often  occurs  only  when  the  recurrent
nfections  have  already  resulted  in  sequelae.
Due  to  the  urgency  in  diagnosis  and  treatment,  this  study
imed  to  validate  the  TRECs  quantiﬁcation  technique  by
RT-PCR  for  NBS  of  SCID  and  to  apply  the  technique  in  Brazil.
The  results  showed  that  after  analyzing  samples  from
,682  newborns,  a  cutoff  value  of  26  TRECs/L  was  reached,
hich  involved  the  retesting  of  0.43%  of  the  samples.  The
echnique  accuracy  was  validated  through  the  quantiﬁcation
f  TRECs  in  ﬁve  previously  diagnosed  cases  of  SCID,  with
esults  varying  from  0  to  2  TRECs/L  (Table  1).  The  retest
ate  of  0.43%  is  within  the  range  reported  in  the  literature
0.20--3.26%)  and  can  be  considered  an  appropriate  value,
mportant  for  the  implementation  of  a full-scale  test,  which
revents  increased  costs  and  unnecessary  expectations  and
tress  for  the  families.14 The  percentage  of  samples  to  be
etested  is  directly  related  to  the  cutoff  value  used,  ranging
rom  7  to  252  TRECs/L  in  the  studies  performed  to  date.
his  is  due  to  the  different  methodologies  used  for  both  DNA
xtraction  and  for  the  PCR  reaction.14
The  cutoff  value  obtained  for  the  samples  (26  TRECs/L)
s  very  close  to  the  value  used  by  Baker  et  al.  (25  TRECs/L),
n  which  this  study  was  based  to  validate  the  tech-
ique  in  the  present  laboratory.3 It  is  noteworthy  that
his  cutoff  value  had  100%  sensitivity  for  detecting  SCID,
ut  recent  studies  have  reported  that  several  other
-lymphopenias  could  also  be  detected  by  this  methodol-
gy:  DiGeorge  syndrome,  trisomy  21,  ataxia-telangiectasia,
risomy  18,  CHARGE  syndrome,  and  cardiac  abnormalities,
mong  others.
The  lower  value  of  TRECs/L  found  in  preterm  infants
as  been  reported  in  other  studies,  which  also  showed  that
he  result  tends  to  normalize  when  the  child  reaches  the
t
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adjusted  gestational  age  of  37  weeks.7,15 Thus,  these  results
are  consistent  with  the  international  literature  and  were
validated  by  positive  disease  controls.
TRECs  quantiﬁcation  by  RT-PCR  was  applied  on  a  small
scale  and  had  an  estimated  cost  of  US$  4  per  sample  in
this  study.  This  value,  although  it  only  considers  the  costs  of
reagents,  can  be  compared  to  the  cost  of  NBS  for  congenital
adrenal  hyperplasia  (CAH),  calculated  according  to  a pilot
study  conducted  in  the  state  of  Goiás,  of  US$  7.16 Consid-
ering  the  number  of  live  births  in  Brazil  in  2013  of  nearly
3  million  children,17 the  total  cost  would  be  approximately
US$  12  million,  less  than  the  NBS  for  CAH,  a  pathol-
ogy  recently  included  in  the  National  Neonatal  Screening
Program.18 It  is  noteworthy  that  it  is  necessary  to  add  addi-
tional  costs  (active  search  and  conﬁrmatory  tests)  to  this
value  and  on  a  large  scale,  this  value  tends  to  decrease.
Among  the  T-lymphopenias  with  the  possibility  of  being
diagnosed  through  the  quantiﬁcation  of  TRECs,  SCID  are
undoubtedly  the  most  severe.  Most  children  with  SCID  are
not  diagnosed  until  several  severe  infections  have  mani-
fested,  or  the  child  shows  failure  to  thrive  and,  unless  there
is  a  family  history  of  SCID,  the  diagnosis  is  often  delayed  and
chances  of  a  cure  are  diminished.  Moreover,  an  irrefutable
argument  for  the  inclusion  of  SCID  in  neonatal  screening  is
the  fact  that  SCID  are  the  only  conditions  identiﬁed  through
neonatal  screening  that  can  be  cured  by  treatment  when  the
diagnosis  is  made  at  an  early  stage.19
Hematopoietic  stem  cell  transplantation  (HSCT)  is  cura-
tive  and  is  available  in  Brazil.5 When  carried  out  before
3.5  months  of  life,  it  results  in  a  95%  survival  rate;  after  that
age,  long-term  survival  decreases  to  60--70%,  and  the  inci-
dence  of  infectious  complications  and  sequelae  increases
dramatically.20 Even  worse  consequences  occur  when  HSCT
is  carried  out  with  active  infections  during  the  procedure:
the  survival  rate  decreases  to  50%,  again  showing  that  early
diagnosis  substantially  improves  the  outcome.14,20
Regarding  the  economic  aspects,  it  is  also  necessary  to
consider  the  costs  of  HSCT  and  of  complications  from  several
infections  to  which  patients  with  SCID  are  subject.  Several
studies  have  compared  the  costs  of  early  vs.  late  HSCT:  the
full  early  treatment,  performed  up  to  3.5  months  of  age
(before  the  infections  occur)  costs  up  to  four  times  less
than  when  performed  after  that  age  (US$  365,785  vs.  US$
1.43  million).21 When  considering  only  the  cost  of  the  trans-
plantation,  the  difference  was  US$  120,000  vs.  US$  360,000
when  HSCT  was  performed  before  and  after  3.5  months
of  age,  respectively.22 These  values,  calculated  for  the
United  States,  show  the  great  beneﬁt  of  neonatal  screening
for  SCID  to  the  detriment  of  high  costs  resulting  from
late  diagnosis  and  the  complications  that  this  delay  may
cause.21
When  analyzing  HSCT  values  before  and  after  the  age
of  3.5  months,  there  is  an  approximate  cost  reduction  of
US$  240,000  when  the  transplantation  is  performed  early.
Considering  the  cost  obtained  for  this  study  of  US$  4,  it
would  be  possible  to  screen  approximately  60,000  children.
Thus,  the  introduction  of  this  test  on  a  large  scale  would
practically  pay  for  itself,  as  the  cost  reduction  generated
with  the  diagnosis  of  a  child  with  SCID  referred  to  earlier
HSCT  would  cover  the  costs  to  perform  the  tests  required
to  diagnose  other  child  (when  considering  the  incidence  of
0.17/10,000).379
It  should  be  noted  that  the  data  presented  herein  reﬂect
he  economic  costs  in  the  US  and  it  is  necessary  for  cost-
eneﬁt  studies  to  be  conducted  in  Brazil,  considering  the
razilian  public  health  system.
The  implementation  of  the  newborn  screening  test
or  SCID  is  increasing  worldwide.  Several  countries  have
ncluded  SCID  in  their  routine  newborn  screening  or  have
ngoing  pilot  studies  (United  States,  Canada,  Iran,  Taiwan,
srael,  Spain,  France,  Sweden,  and  the  United  Kingdom).19,23
he  implementation  as  a  routine  in  Brazil  could  signiﬁcantly
mprove  the  aforementioned  tragic  scenario,  without  the
eed  for  a  new  platform.
The  application  of  quantiﬁcation  of  TRECs  in  the  neona-
al  screening  of  8,682  newborns  resulted  in  a  cutoff  value
f  26  TRECs/L,  with  a  retest  rate  similar  to  that  in  inter-
ational  studies.  This  study  showed  that  the  technique  is
easible  and  can  be  implemented  on  a  large  scale  after
echnical  training  of  the  involved  teams.
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